
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license in New Hampshire, enabling the company to start U.S. manufacturing of its proprietary Alpha DaRT technology, set to begin in 2026. The company maintains a strong cash position, which supports its ongoing development and manufacturing efforts in the lucrative oncology market. Although Alpha Tau reported a net loss of $11.7 million, which was slightly higher than previous estimates, the potential of Alpha DaRT to meet unmet needs in oncology remains a key driver for investor interest and future growth.
Bears say
Alpha Tau Medical reported a net loss of $11.7 million in the third quarter of 2025, highlighting its ongoing financial struggles as a clinical-stage oncology company. The outlook for the company's proprietary Alpha DaRT technology is clouded by significant risks, including potential failures in clinical trials, challenges in obtaining regulatory approval in the U.S., and difficulties in achieving commercial success due to market limitations and competition. Additionally, the presence of potential dilution risks may further undermine investor confidence and the overall financial stability of Alpha Tau Medical.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares